Celgene Corp is incorporated in Delaware in 1986. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST, IMNOVID, THALOMID (inclusive of Thalidomide Celgene, ISTODAX and azacitidine for injection (generic version of VIDAZA). It owns and operates a manufacturing facility in Zofingen, Switzerland which produces the active pharmaceutical ingredient (API) for REVLIMID and THALOMID and have contracted with third-party contract manufacturers to provide backup API manufacturing services for these products. Manufacturing services for REVLIMID and THALOMID, which consist of formulation, encapsulation, packaging, warehousing and distribution, are performed at our drug product manufacturing facility in Boudry, Switzerland. The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.